The UK-based cell therapy company Autolus Therapeutics Plc has appointed Robert Dolski as chief financial officer, effective 7 August. He joins from Checkmate Pharmaceuticals Inc where he was also CFO. Checkmate was acquired by Regeneron Pharmaceuticals Inc in 2022. Mr Dolski brings more than 20 years of experience as a life science financial executive in both private and public companies. Separately, Veronica Hersberger has joined Autolus to lead medical affairs ahead of the expected registration and launch of Autolus’ CAR T cell therapy for acute lymphocytic leukaemia, obecabtagene autoleucel (obe-cel). Additionally, Miranda Neville has been promoted as head of project management to lead the obe-cel programme.
Autolus Therapeutics announced the appointments on 19 July 2023.
Copyright 2023 Evernow Publishing Ltd